Roselabs Peer Comparison

BSE: 535503

₹7.70

₹0.36 (4.90%)

As on 23-Dec-2015IST

Market cap

₹8 Cr

Revenue (TTM)

₹6 Cr

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Edit

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	8	35,548	28,659	28,019	28,577
Revenue (₹ Cr)	6	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-0.35	414.00	288.22	387.35	-371.81
Net Margin (%)	-6.11	11.23	14.79	26.01	-3.93
RoE (%)	-2.69	8.38	29.77	25.18	-3.85
Price to Earnings	--	86.91	99.43	72.55	--
Price-To-Book	0.79	7.06	21.35	16.24	3.57

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	33.11	4,481.54	39.21	111.75	--
Total Income	33.11	4,548.09	39.54	111.77	--
Total Expenditure	33.15	3,772.14	28.05	103.45	--
EBITDA	-0.04	709.40	11.16	8.29	--
Depreciation	0.23	145.40	5.18	0.72	--
EBIT	-0.27	564.00	5.98	7.58	--
Interest	0.52	55.21	2.37	1.59	--
Other Income	0.00	66.55	0.33	0.02	--
Exceptional Items	--	49.83	--	--	--
Profit before Tax	-0.79	575.34	3.94	6.01	--
Provision for Tax	-0.02	162.65	1.27	1.91	--
Profit after Tax	-0.78	412.69	2.67	4.10	--

Liabilities (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	11.95	3,715.35	47.49	14.83	--
Minority Interest	--	143.95	--	--	--
Non-Current Liabilities	1.32	1,872.46	11.98	6.27	--
Current Liabilities	20.49	1,772.97	24.42	37.80	--
Total Liabilities	33.76	7,504.73	83.90	59.21	--

Assets (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	8.40	3,983.17	53.02	11.26	--
Current Assets	25.36	3,521.56	30.88	47.65	--
Total Assets	33.76	7,504.73	83.90	59.21	--
Total Debt*	10.75	2,010.07	26.03	22.92	--
Net Current Assets	4.87	1,748.59	6.46	9.84	--
Contingent Liabilities	--	295.45	4.70	--	--

Cashflow (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	0.06	354.96	10.55	-3.88	--
Cash Flow from Investing Activities	-0.36	-206.63	-5.46	-4.44	--
Cash from Financing Activities	-0.43	-75.65	-10.21	8.61	--
Net Cash Inflow / Outflow	-0.73	72.68	0.34	0.29	--

Ratios

Profitability Ratios

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	-1.15	11.25	9.04	25.03	--
ROE (%)	-7.68	12.49	9.82	31.99	--
ROA (%)	-1.69	5.84	3.33	8.42	--
EBIT Margin (%)	-0.11	17.31	29.29	7.44	--
Net Margin (%)	-2.34	9.07	6.75	3.66	--
Cash Profit Margin (%)	-1.64	12.43	19.93	4.31	--

Growth Ratios

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-62.64	-7.22	-5.70	46.82	--
EBIT Growth (%)	-102.32	-27.08	-2.08	24.42	--
Net Profit Growth (%)	-908.61	-51.03	-40.70	42.98	--
EPS Growth (%)	-908.61	-42.48	-40.70	42.98	--
Book Value Growth (%)	-7.40	4.11	10.33	37.67	--

Valuation Ratios

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	46.73	0.00	0.00	--
Price / Book Value	1.04	6.09	0.00	0.00	--
Dividend Yield (%)	0.00	1.07	--	--	--
EV/EBITDA	-548.22	27.84	4.00	2.87	--
Market Cap (₹ Cr)	10.06	20,529.92	0.00	0.00	--

Solvency Ratios

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	1.11	0.55	0.55	1.55	--
Short term debt to equity ratio	0.82	0.09	0.27	0.97	--
Current Ratio	1.24	1.99	1.26	1.26	--
Quick Ratio	1.15	1.41	1.22	0.89	--
Interest Coverage	-0.51	11.42	2.66	4.78	--

Operating Efficiency Ratios

	Roselabs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	49.65	16.54	42.87	21.80	--
Asset Turnover	0.72	0.64	0.49	2.30	--
Receivable days	292.59	49.71	143.12	61.92	--
Inventory Days	17.44	81.88	10.03	41.26	--
Payable days	234.09	136.23	216.06	94.00	--
Cash Conversion Cycle	75.95	-4.64	-62.91	9.17	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly